-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History --
-- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million --
-- New Mammalian and Cell and Gene Therapy Facilities Fully Operational and in Service; Capital Expenditure Associated with Three-Year Expansion Program Completed --
-- FY 2025 Revenue Guidance of Between $160 Million and $168 Million --
TUSTIN, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the fourth quarter and year ended April 30, 2024.
Highlights from the Quarter Ended April 30, 2024, and Other Events:
“The fourth quarter of fiscal 2024 was a high point for the company,” stated Nick Green, president and CEO of Avid Bioservices. “We generated the highest quarterly revenues in Avid’s history, meeting our current revenue expectations for the year. During the period we signed multiple new project agreements, and we continue to see positive signs for business development in the year ahead. Given our strong backlog and robust proposal pipeline we are looking ahead to a promising 2025, and are providing 2025 full fiscal year revenue guidance of between $160 million and $168 million, representing 17% growth year-over-year at the midpoint.
“Supporting our optimism, is the growing interest we’ve seen in our newly completed facilities and expanded capabilities. In late fiscal 2023, we unveiled our completed mammalian cell facilities expansion, and during fiscal 2024, the company completed and launched its new cell and gene therapy (CGT) manufacturing facility. With the completion of this three-year construction program, the company has dramatically expanded its capacity and technical capabilities and increased the company’s annual revenue generating capacity from approximately $120 million annually in fiscal 2021 to more than $400 million annually.
“The enhancements and expansion not only allow Avid to better serve its new and existing biotech customers but, importantly, enable the company to address the needs of large pharma as well. The expanded addressable market and improvements in the broader business environment have resulted in an increase in larger and later stage programs in our production pipeline. With respect to capacity, our utilization is expected to increase as we onboard and execute new programs in both our mammalian and CGT facilities. As we’ve discussed in prior quarters, this expected increase in utilization should improve our margins.
“We ended the year in a position of strength with positive revenue momentum building, particularly in the second half of fiscal 2024, continued new business wins and line of sight to margin expansion. We recorded our highest ever quarterly revenue of $43.0 million in Q4, logged our highest record backlog of $206 million in Q3 and ended fiscal 2024 with near double our gross margin in Q4 as compared to Q3 of the fiscal year. We expect the commercial momentum and margin improvements to continue in the year ahead given our strong backlog and anticipated increase in capacity utilization. Importantly, we expect to generate positive cash flow during fiscal 2025.”
Financial Highlights and Guidance
More detailed financial information and analysis may be found in Avid Bioservices’ Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission today.
Recent Corporate Developments
Statement Regarding Use of Non-GAAP Financial Measures
The company uses certain non-GAAP financial measures such as non-GAAP adjusted net income, free cash flow, as well as adjusted EBITDA. The company uses these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. The company believes that they provide useful information about operating results, enhance the overall understanding of its operating performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making. These non-GAAP financial measures exclude amounts that the company does not consider part of ongoing operating results when planning and forecasting and when assessing the performance of the organization and its senior management. The company computes non-GAAP financial measures primarily using the same consistent method from quarter to quarter and year to year, and may consider whether other significant items that arise in the future should be excluded from its non-GAAP financial measures.
The company reports non-GAAP financial measures in addition to, and not as a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. generally accepted accounting principles (GAAP). These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. The company believes that non-GAAP financial measures should only be used to evaluate its results of operations in conjunction with the corresponding GAAP financial measures and encourages investors to carefully consider its results under GAAP, as well as the supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business.
Non-GAAP net income (loss) excludes stock-based compensation; business transition and related costs including, but not limited to, corporate initiatives into new business activities such as severance and related expenses; non-cash interest expense on debt; and other income or expense items and is adjusted for income taxes. Adjusted EBITDA excludes non-cash operating charges for stock-based compensation, depreciation, and amortization as well as non-operating items such as interest income, interest expense, and income tax expense or benefit and is adjusted for income taxes. For the reasons explained above, adjusted EBITDA also excludes certain business transition and related costs. The company also uses measures such as free cash flow, which represents cash flow provided by or (used in) operations less cash used in the acquisition and disposition of capital.
Additionally, non-GAAP net income (loss) and adjusted EBITDA are key components of the financial metrics utilized by the company’s compensation committee to measure, in part, management’s performance and determine significant elements of management’s compensation. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP financial measures are included at the end of this press release.
Webcast
Avid will host a webcast on Tuesday, July 2, 2024, at 4:30 PM Eastern (1:30 PM Pacific). To listen to the live webcast, or access the archived webcast, please visit: https://ir.avidbio.com/investor-events.
About Avid Bioservices, Inc.
Avid Bioservices (NASDAQ: CDMO) is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With more than 30 years of experience producing biologics, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
Forward-Looking Statements
Statements in this press release, which are not purely historical, including statements regarding the company’s projected revenue ramp and expected continued momentum, expected future sustained profitability, the estimated annual revenue-generating capacity of the company’s facilities, the expected benefits to the company’s business from customers with later stage programs, the anticipated timing for recognizing revenue from the company’s backlog, the realization of the company’s strategic objectives, the company’s revenue guidance, and other statements relating to the company’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, including, but not limited to, the risk the company may experience delays in engaging new customers, the risk that the company may not be successful in executing customers projects, the risk that changing economic conditions may delay or otherwise adversely impact the realization of the company’s backlog, the risk that the company may not be able to convert its backlog into revenue within the contemplated time periods, the risk that the company may experience technical difficulties in completing customer projects due to unanticipated equipment and/or manufacturing facility issues which could result in projects being terminated or delay delivery of products to customers, revenue recognition and receipt of payment or result in the loss of the customer, the risk that the company’s later-stage customers do not receive regulatory approval or that commercial demand for an approved product is less than forecast, the risk that one or more existing customers terminates its contract prior to completion or reduces or delays its demand for development or manufacturing services which could adversely affect guided fiscal 2025 revenues, the risk that expanding into a new biologics manufacturing capability may distract senior management’s focus on the company’s existing operations, the risk that the company may experience delays in hiring qualified individuals into the cell and gene therapy business, the risk that the company may experience delays in engaging customers for the cell and gene therapy business, and the risk that the cell and gene therapy business may not become profitable for several years, if ever. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2024, as well as any updates to these risk factors filed from time to time in our other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release, and we disclaim any obligation, and do not undertake, to update or revise any forward-looking statements in this press release except as may be required by law.
| AVID BIOSERVICES, INC. CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) (In thousands, except per share information) | |||||||||||||||
| Three Months Ended April 30, |
Twelve Months Ended April 30, |
||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenues | $ | 42,975 | $ | 39,799 | $ | 139,911 | $ | 149,266 | |||||||
| Cost of revenues | 37,475 | 31,408 | 132,593 | 117,786 | |||||||||||
| Gross profit | 5,500 | 8,391 | 7,318 | 31,480 | |||||||||||
| Operating expenses: | |||||||||||||||
| Selling, general and administrative | 6,794 | 7,559 | 25,996 | 27,879 | |||||||||||
| Total operating expenses | 6,794 | 7,559 | 25,996 | 27,879 | |||||||||||
| Operating income (loss) | (1,294 | ) | 832 | (18,678 | ) | 3,601 | |||||||||
| Interest expense | (1,810 | ) | (659 | ) | (4,337 | ) | (3,013 | ) | |||||||
| Other income (expense), net | (2,126 | ) | 375 | (3,912 | ) | 1,002 | |||||||||
| Net income (loss) before income taxes | (5,230 | ) | 548 | (26,927 | ) | 1,590 | |||||||||
| Income tax expense | 117,874 | 883 | 113,826 | 1,331 | |||||||||||
| Net income (loss) | $ | (123,104 | ) | $ | (335 | ) | $ | (140,753 | ) | $ | 259 | ||||
| Comprehensive income (loss) | $ | (123,104 | ) | $ | (335 | ) | $ | (140,753 | ) | $ | 259 | ||||
| Net income (loss) per share: | |||||||||||||||
| Basic | $ | (1.94 | ) | $ | (0.01 | ) | $ | (2.23 | ) | $ | 0.00 | ||||
| Diluted | $ | (1.94 | ) | $ | (0.01 | ) | $ | (2.23 | ) | $ | 0.00 | ||||
| Weighted average common shares outstanding: | |||||||||||||||
| Basic | 63,496 | 62,587 | 63,199 | 62,268 | |||||||||||
| Diluted | 63,496 | 62,587 | 63,199 | 63,782 |
| AVID BIOSERVICES, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except par value) | |||||||
| April 30, 2024 |
April 30, 2023 |
||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 38,106 | $ | 38,542 | |||
| Accounts receivable, net | 16,644 | 18,298 | |||||
| Contract assets | 12,364 | 9,609 | |||||
| Inventory | 30,375 | 43,908 | |||||
| Prepaid expenses and other current assets | 6,513 | 2,094 | |||||
| Total current assets | 104,002 | 112,451 | |||||
| Property and equipment, net | 186,514 | 177,770 | |||||
| Operating lease right-of-use assets | 41,157 | 42,772 | |||||
| Deferred tax assets | — | 113,751 | |||||
| Other assets | 4,884 | 4,473 | |||||
| Restricted cash | — | 350 | |||||
| Total assets | $ | 336,557 | $ | 451,567 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 20,667 | $ | 24,593 | |||
| Accrued compensation and benefits | 5,437 | 8,780 | |||||
| Contract liabilities | 39,887 | 37,352 | |||||
| Convertible senior notes, net | — | 140,623 | |||||
| Current portion of operating lease liabilities | 1,354 | 1,358 | |||||
| Other current liabilities | 3,221 | 2,440 | |||||
| Total current liabilities | 70,566 | 215,146 | |||||
| Convertible senior notes, net | 153,593 | — | |||||
| Operating lease liabilities, less current portion | 44,336 | 45,690 | |||||
| Finance lease liabilities, less current portion | 7,101 | 1,562 | |||||
| Deferred tax liabilities | 72 | — | |||||
| Total liabilities | 275,668 | 262,398 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates | — | — | |||||
| Common stock, $0.001 par value; 150,000 shares authorized; 63,568 and 62,692 shares issued and outstanding at respective dates | 64 | 63 | |||||
| Additional paid-in capital | 632,696 | 620,224 | |||||
| Accumulated deficit | (571,871 | ) | (431,118 | ) | |||
| Total stockholders’ equity | 60,889 | 189,169 | |||||
| Total liabilities and stockholders’ equity | $ | 336,557 | $ | 451,567 |
| AVID BIOSERVICES, INC. ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP FINANCIAL MEASURES (Unaudited) (In thousands) | |||||||||||||||
| Three Months Ended April 30, |
Twelve Months Ended April 30, |
||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| GAAP net income (loss) | $ | (123,104 | ) | $ | (335 | ) | $ | (140,753 | ) | $ | 259 | ||||
| Income tax expense | 117,874 | 883 | 113,826 | 1,331 | |||||||||||
| GAAP net income (loss) before income taxes | $ | (5,230 | ) | $ | 548 | $ | (26,927 | ) | $ | 1,590 | |||||
| Adjustments: | |||||||||||||||
| Stock-based compensation | 2,463 | 3,551 | 9,731 | 10,978 | |||||||||||
| Non-cash interest expense | 588 | 264 | 1,503 | 1,046 | |||||||||||
| Loss on extinguishment of debt | 1,865 | — | 1,865 | — | |||||||||||
| Unrealized loss on equity investment | 423 | — | 2,817 | — | |||||||||||
| Income tax effect of adjustments | 4,655 | (403 | ) | 2,795 | (2,504 | ) | |||||||||
| Adjusted net income (loss) | $ | 4,764 | $ | 3,960 | $ | (8,216 | ) | $ | 11,110 | ||||||
| GAAP net income (loss) | $ | (123,104 | ) | $ | (335 | ) | $ | (140,753 | ) | $ | 259 | ||||
| Interest expense, net | 1,505 | 281 | 3,387 | 1,926 | |||||||||||
| Income tax expense | 117,874 | 883 | 113,826 | 1,331 | |||||||||||
| Depreciation and amortization | 2,859 | 1,884 | 11,109 | 7,210 | |||||||||||
| Stock-based compensation | 2,463 | 3,551 | 9,731 | 10,978 | |||||||||||
| Loss on extinguishment of debt | 1,865 | — | 1,865 | — | |||||||||||
| Unrealized loss on equity investment | 423 | — | 2,817 | — | |||||||||||
| Adjusted EBITDA | $ | 3,885 | $ | 6,264 | $ | 1,982 | $ | 21,704 | |||||||
| GAAP net cash provided by (used in) operating activities | $ | 1,257 | $ | 3,145 | $ | 10,952 | $ | (12,722 | ) | ||||||
| Purchase of property and equipment | (5,693 | ) | (25,223 | ) | (31,805 | ) | |
(77,803 | ) | ||||||
| Free cash flow | $ | (4,436 | ) | $ | (22,078 | ) | $ | (20,853 | ) | $ | (90,525 | ) |
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com